Advocacy intelligence hub — real-time data for patient organizations
University of Nottingham
Lovisenberg Diakonale Hospital — NA
Sucraid: FDA approved
Oral replacement therapy of the genetically determined sucrase deficiency, which is part of congenital sucrease-isomaltase deficiency.
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
Sucraid
QOL Medical, LLC
Sucraid
(Sacrosidase)Orphan drugQOL Medical, LLC
Sucrose-specific Enzyme [EPC]
Normocarb HF
(bicarbonate infusate)Orphan drugstandardDialysis Solutions, Inc.
Cimetidine
(CIMETIDINE)Orphan drugstandardChartwell RX, LLC
Histamine-2 Receptor Antagonist [EPC]
Priya Kishnani, MD
Duke University
📍 DURHAM, NC
Whu-Liang Hwu, MD, PhD
National Taiwan University Hospital
Priya S Kishnani, MD
Duke University
📍 DURHAM, NC
Marit E Jørgensen, Prof.
Steno Diabetes Center Greenland
Weng Tao, M.D., Ph. D
QOL Medical
Cecilia Kennback, Nurse
Department of Internal Medicine, Skåne University Hospital, Malmö
View all Congenital sucrase-isomaltase deficiency specialists →